InsiderTrades

Form 4 for IMA ImageneBio, Inc.

Accepted 2025-07-29 00:00:00 ET · period of report 2025-07-25 · accession 0000950170-25-099848 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-07-29 2025-07-28 IMA Marango Jotin CFO F - Tax $17.16 -4,630 11.1K -29% -$79.5K
D 2025-07-29 2025-07-28 IMA Marango Jotin CFO A - Grant — +15.8K 15.8K New —
DM 2025-07-29 2025-07-25 IMA Marango Jotin CFO D - Sale to Iss $0.00 -683.2K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-07-28 F D 4,630 $17.16 11,146 D — —
2 Common Common Stock 2025-07-28 A A 15,776 — 15,776 D — — (F1) In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena.
3 Derivative Stock Option (Right to Buy) 2025-07-25 D D 397,199 $0.00 0 D — · — to — 397,199 Common Stock (F1) In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena.
4 Derivative Stock Option (Right to Buy) 2025-07-25 D D 105,000 $0.00 0 D — · — to — 105,000 Common Stock (F1) In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena.
5 Derivative Stock Option (Right to Buy) 2025-07-25 D D 181,000 $0.00 0 D — · — to — 181,000 Common Stock (F1) In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena.